Nuvation Bio Inc. (NUVB)
NYSE: NUVB · IEX Real-Time Price · USD
2.705
+0.025 (0.93%)
Apr 23, 2024, 1:59 PM EDT - Market open

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.

The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc.
Nuvation Bio logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Dr. David T. Hung M.D.

Contact Details

Address:
357 Tehama Street, Floor 3
San Francisco, California 94103
United States
Phone (415) 754-3517
Website nuvationbio.com

Stock Details

Ticker Symbol NUVB
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001811063
CUSIP Number 67080N101
ISIN Number US67080N1019
Employer ID 85-0862255
SIC Code 2834

Key Executives

Name Position
Dr. David T. Hung M.D. Founder, President, Chief Executive Officer and Director
Dr. David C. Hanley Ph.D. Chief Technical Operations Officer
Moses Makunje Principal Accounting Officer and Principal Financial Officer
Dr. Gary Hattersley Ph.D. Chief Scientific Officer
Stacy Markel Chief People Officer
Kerry A. Wentworth Chief Regulatory Officer
Dr. David Liu M.D., Ph.D. Chief Medical Officer
Colleen Sjogren Chief Commercial Officer

Latest SEC Filings

Date Type Title
Apr 18, 2024 S-8 Securities to be offered to employees in employee benefit plans
Apr 10, 2024 8-K Current Report
Mar 26, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 25, 2024 8-K Current Report
Mar 4, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 29, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report